JP MORGAN/CALL/BECTON DICKINSON AND CO./305/0.1/17.01.25 Share Price

Warrant

DE000JL2F6L9

Market Closed - Bid/Ask 09:52:45 21/05/2024 BST After market 19:47:52
0.34 EUR -5.56% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./305/0.1/17.01.25 0.35 +2.94%
Current month-18.18%
1 month-18.18%
Date Price Change
21/05/24 0.34 -5.56%
20/05/24 0.36 0.00%
17/05/24 0.36 -12.20%
16/05/24 0.41 +7.89%
15/05/24 0.38 -7.32%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 09:52 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL2F6L
ISINDE000JL2F6L9
Date issued 24/04/2023
Strike 305 $
Maturity 17/01/2025 (241 Days)
Parity 10 : 1
Emission price 1.86
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.08
Lowest since issue 0.34
Spread 0.08
Spread %20.00%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus